Savara (SVRA) Prices Public Offering of Common Stock, Warrants
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/23/2026
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- BofA's Hartnett sees dollar slump, risk selloff if bond intervention fails
- Applied Optoelectronics sets up $600M at-the-market stock offering
- Fannie Mae loses at least 10 senior executives amid departures - WSJ
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- Morgan Stanley course-corrects their semiconductor equipment outlook on demand
- One killed, three injured when man attacks Swedish school with sword
Oppenheimer Starts Savara (SVRA) at Outperform
March 15, 2021 5:46 AM EDTOppenheimer analyst Francois Brisebois initiates coverage on Savara (NASDAQ: SVRA) with a Outperform rating and a price target of $4.00.
The analyst comments "Savara (SVRA) has recently simplified the company to focus solely on its main value driver, molgramostim nebulizer solution (molgramostim) for Autoimmune Pulmonary... More
Savara (SVRA) Stock Offering is Said to Price at $1.45 Per Share - Bloomberg
March 11, 2021 8:56 AM ESTSavara (NASDAQ: SVRA) Stock Offering is Said to Price at $1.45 Per Share - Bloomberg
Savara (SVRA) Announces Proposed Public Offering of Common Stock
March 10, 2021 4:49 PM ESTSavara Inc. (Nasdaq:... More
